$0.80
-0.15 (-15.38%)
Open$0.94
Previous Close$0.95
Day High$0.94
Day Low$0.76
52W High$1.51
52W Low$0.63
Volume—
Avg Volume379.8K
Market Cap10.21M
P/E Ratio—
EPS$-0.53
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+3,347.3% upside
Current
$0.80
$0.80
Target
$27.73
$27.73
$20.43
$27.73 avg
$35.07
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.57M | 1.60M | 1.25M |
| Net Income | 4.2K | 5.8K | 3.4K |
| Profit Margin | 0.3% | 0.4% | 0.3% |
| EBITDA | 8.2K | 8.5K | 6.5K |
| Free Cash Flow | 4.7K | 4.2K | 2.8K |
| Rev Growth | -8.5% | +15.0% | -6.0% |
| Debt/Equity | 0.92 | 0.88 | 0.96 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |